Respiri (ASX:RSH) - Executive Chairman, Nicholas Smedley
Executive Chairman, Nicholas Smedley
Source: Business Insider
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • eHealth company Respiri (RSH) has partnered with Entech Electronics for the global supply of its wheezo device
  • Respiri’s trademark wheezo device is an innovative technology which monitors wheezing to manage and improve asthma symptoms
  • This partnership will enable the company to significantly scale-up production to meet the forecasted global demand
  • Respiri has placed its first orders and Entech is preparing to begin production at its facility in Shenzhen, China
  • All up, 12,000 additional wheezo devices have been commissioned for delivery from February 2021
  • Company shares are trading 4.55 per cent higher, worth 23 cents each

eHealth company Respiri (RSH) has appointed Entech Electronics as its global manufacturing partner to supply its wheezo device.

Entech Electronics is an Australian-based contract electronics manufacturer and has over 34 years’ experience in the industry.

Respiri has now placed its first orders for the wheezo device, while Entech is preparing to begin production at its facility in Shenzhen, China.

“Our operation in Shenzhen has commenced investment in assembly and test equipment that will allow us to scale quickly and react to Respiri’s forecast growing global demand and accommodate monthly volume requirements well in excess of 10,000 devices,” Entech Electronics CEO Wayne Hoffman said.

A total of 12,000 additional wheezo devices have been commissioned for delivery from February 2021.

This partnership will enable Respiri to significantly scale-up production to meet the forecasted global demand.

“We are delighted to partner with Entech Electronics as they are well placed to support our global product volume requirements at cost positions that support Respiri’s business model,” Respiri CEO and Managing Director Marjan Mikel said.

Respiri’s Wheezo device is an innovative technology which monitors wheezing to manage and improve asthma. The technology also facilitates data sharing between caregivers, physicians and other health care professionals.

Company shares are trading 4.55 per cent higher, worth 23 cents each at 10:52 am AEST.

RSH by the numbers
More From The Market Online

OncoSil’s cancer device shows shrink in pancreatic tumours

OncoSil's cancer device shows shrink in pancreatic tumours at a study conducted at the Royal Adelaide…
The Market Online Video

Why Princeton Professor rates BlinkLab’s autism & ADHD screening app

In this interview with Sonia Madigan, Professor Sam Wang of Princeton University discusses the development and…

Orthocell’s Remplir shows 85% success rate in nerve repair study

Orthocell's medical device RemplirTM shows 85% success rate in latest nerve repair study, holding a promise…

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.